CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered Viracta (VRx)-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03397706
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:43.844176+00:00
Published At: 2025-03-20T00:00:00+00:00
Record Updated At: 2025-03-20
Results Posted At: 2025-03-20
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Epstein-Barr Virus-Associated Lymphoma", "Lymphoproliferative Disorders"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-03-20"
protocolSection.identificationModule.nctId: "NCT03397706"
protocolSection.identificationModule.officialTitle: "A Phase 1b/2 Open-Label, Dose Escalation \u0026 Expansion Study of Orally Administered Viracta (VRx)-3996 \u0026 Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-03-20"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.